Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607994 | 0.87 | NLRP3 (0.52) | NLRP3MAPK1SMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL3596396 | 0.84 | NLRP3 (0.60) | NLRP3SMN1; SMN2NPC1CYP1A2CYP2C9 | |
| SCHEMBL3607558 | 0.82 | MAPT (0.49) | NLRP3MAPK1CSNK2A2CSNK2A1SMN1; SMN2 | |
| SCHEMBL2281889 | 0.74 | HPGD (0.50) | MAPK1TSHRSMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL348699 | 0.72 | SMN1; SMN2 (0.50) | NLRP3SMN1; SMN2HPGDKDM4E | |
| SCHEMBL4088389 | 0.71 | TSHR (0.54) | NLRP3TSHRHPGDRAB9AKDM4E | |
| SCHEMBL347037 | 0.69 | SRC (0.51) | SRCMAPK1SMN1; SMN2HPGD | |
| SCHEMBL3106591 | 0.69 | FFAR1 (0.46) | SMN1; SMN2HPGDKDM4E | |
| SCHEMBL3492711 | 0.69 | CSNK2A2 (0.38) | MAPK1CSNK2A2CSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL4852614 | 0.68 | NLRP3 (0.63) | NLRP3MAPK1TSHRSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| US-7601870-B2 | Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy | H. LUNDBECK A/S (DK) | 2009-10-13 | — | — | US | disclosed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | NDUFS3, NAT1, PRMT3 | NLRP3 3233/4885SRC 1133/4885MAPK1 2784/4885 |
| US-20060155121-A1 | Substituted aniline derivatives | UGT2B7, NAT1, CYP1A2 | NLRP3 4464/4885SRC 1585/4885MAPK1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.